TA
PACB icon

Tactive Advisors’s Pacific Biosciences PACB Stock Holding History

Tactive Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,097
Closed -$24.5K – 282
2025
Q4 		$24.5K Sell
13,097
-1,386
-10% -$2.66K 0.01% 255
2025
Q3 		$18.5K Sell
14,483
-3,954
-21% -$5.36K 0.01% 252
2025
Q2 		$22.9K Buy
+18,437
New +$21.3K 0.01% 227

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Tactive Advisors's PACB Position: Q1 2026 in Review

Tactive Advisors sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 13,097 shares — an estimated $24.5K sold.

Tactive Advisors first reported a position in PACB in Q2 2025 and held it in 3 quarters. The position peaked at $24.5K in Q4 2025. 231 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Tactive Advisors reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
  • Tactive Advisors sold 13,097 Pacific Biosciences shares in Q1 2026, an estimated $24.5K.
  • Tactive Advisors first reported a position in Pacific Biosciences in Q2 2025 and held it in 3 quarters.
  • Tactive Advisors's Pacific Biosciences position peaked at $24.5K in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Tactive Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.